Synopsis
Synopsis
0
JDMF
0
VMF
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Alfetim
2. Alfusozine
3. Alfuzosin
4. Alphuzosine
5. Benestan
6. N-(3-((4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-2-furancarboxamide
7. Urion
8. Uroxatral
9. Xatral
1. 81403-68-1
2. Alfuzosin Hcl
3. Uroxatral
4. Urion
5. Xatral
6. Alfoten
7. Alfuzosin (hydrochloride)
8. Sl 77 499-10
9. Sl 77499-10
10. Alfuzosinhydrochloride
11. Sl-77499-10
12. 75046a1xtn
13. Alfuzosin Hydrochloride (uroxatral)
14. Alfetim
15. Sl-77-499-10
16. Dsstox_cid_25514
17. Dsstox_rid_80924
18. Dsstox_gsid_45514
19. N-(3-((4-amino-6,7-dimethoxyquinazolin-2-yl)(methyl)amino)propyl)tetrahydrofuran-2-carboxamide Hydrochloride
20. N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]oxolane-2-carboxamide;hydrochloride
21. Sl-7749910
22. 81403-68-1 (alfuzosin Hcl), 81403-80-7(alfuzosin).
23. Alfuzosin Hydrochloride [usan]
24. Xatral Retard
25. Xatral Od
26. Xatral Sr
27. Xatral Xl
28. Chebi:32286
29. Uroxatral (tn)
30. N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furancarboxamide, Monohydrochloride
31. Unii-75046a1xtn
32. N-(3-((4-amino-6,7-dimethoxyquinazolin-2-yl)
33. Sr-01000759345
34. Alfuzosin Hydrochloride (jan/usan)
35. Alfuzosin Hydrochloride [usan:usp]
36. Mfcd00879135
37. Sl-77499
38. Alfuzosin Hydrochloride;
39. Ncgc00016946-01
40. Sl77.0499-10
41. Cas-81403-68-1
42. Sl-77.0499-10
43. Alfuzosin Hydrochloride,(s)
44. Chembl1723
45. Alfuzosin-[d3] Hydrochloride
46. Schembl179910
47. Dtxsid3045514
48. Alfuzosin For Peak Identification
49. Hy-b0192a
50. Alfuzosin For System Suitability A
51. Bcpp000417
52. Hms1569a05
53. Alfuzosin Hydrochloride [mi]
54. Tox21_110701
55. Tox21_500224
56. Alfuzosin Hydrochloride [jan]
57. S1409
58. (methyl)amino)propyl)tetrahydrofuran-2
59. Akos015966770
60. Tox21_110701_1
61. Ac-1116
62. Alfuzosin Hydrochloride [mart.]
63. Bcp9000271
64. Ccg-213373
65. Lp00224
66. Alfuzosin Hydrochloride [usp-rs]
67. Alfuzosin Hydrochloride [who-dd]
68. Ncgc00095152-09
69. Ncgc00260909-01
70. 2-furancarboxamide, N-(3-((4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-, Monohydrochloride (+-)-
71. As-14240
72. Alfuzosin Hydrochloride [orange Book]
73. Ft-0630890
74. Sw196913-4
75. Alfuzosin Hydrochloride [ep Monograph]
76. Alfuzosin Hydrochloride [usp Monograph]
77. D01692
78. T71347
79. Alfuzosin Hydrochloride, >=98% (hplc), Solid
80. 403a681
81. A840121
82. Sr-01000759345-5
83. Q27114856
84. Alfuzosin Hydrochloride, European Pharmacopoeia (ep) Reference Standard
85. Alfuzosin Hydrochloride, United States Pharmacopeia (usp) Reference Standard
86. Alfuzosin For Peak Identification, European Pharmacopoeia (ep) Reference Standard
87. Alfuzosin For System Suitability A, European Pharmacopoeia (ep) Reference Standard
88. Alfuzosin For System Suitability, European Pharmacopoeia (ep) Reference Standard
89. Alfuzosin Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
90. (+/-)-n-(3-((4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-2-furamide Monohydrochloride
91. 2-furancarboxamide, (+/-)-n-(3-((4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-, Monohydrochloride
92. 4-amino-6,7-dimethoxy-2-[methyl[3-[(tetrahydro-2-furoyl)amino]propyl]amino]quinazoline Hydrochloride
93. N-(3-((4-amino-6,7-dimethoxyquinazolin-2-yl)(methyl)amino)-propyl)tetrahydrofuran-2-carboxamide Hydrochloride
94. N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)(methyl)amino]propyl]tetrahydro-2-furancarboxamide Hydrochloride
95. N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furancarboxamide Hydrochloride
Molecular Weight | 425.9 g/mol |
---|---|
Molecular Formula | C19H28ClN5O4 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 8 |
Exact Mass | 425.1829821 g/mol |
Monoisotopic Mass | 425.1829821 g/mol |
Topological Polar Surface Area | 112 Ų |
Heavy Atom Count | 29 |
Formal Charge | 0 |
Complexity | 511 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Alfuzosin hydrochloride |
Drug Label | Each alfuzosin hydrochloride extended-release tablet contains 10 mg alfuzosin hydrochloride as the active ingredient. Alfuzosin hydrochloride is a white to off-white powder that melts at 231 to 233C. It is freely soluble in water, sparingly solub... |
Active Ingredient | Alfuzosin hydrochloride |
Dosage Form | Tablet, extended release |
Route | Oral |
Strength | 10mg |
Market Status | Prescription |
Company | Wockhardt; Teva Pharms; Apotex; Aurobindo Pharma; Torrent Pharms; Invagen Pharms; Sun Pharma Global; Mylan |
2 of 4 | |
---|---|
Drug Name | Uroxatral |
PubMed Health | Alfuzosin (By mouth) |
Drug Classes | Benign Prostatic Hypertrophy Agent |
Drug Label | Each UROXATRAL extended-release tablet contains 10 mg alfuzosin hydrochloride as the active ingredient. Alfuzosin hydrochloride is a white to off-white crystalline powder that melts at approximately 240C. It is freely soluble in water, sparingly so... |
Active Ingredient | Alfuzosin hydrochloride |
Dosage Form | Tablet, extended release |
Route | Oral |
Strength | 10mg |
Market Status | Prescription |
Company | Covis Pharma Sarl |
3 of 4 | |
---|---|
Drug Name | Alfuzosin hydrochloride |
Drug Label | Each alfuzosin hydrochloride extended-release tablet contains 10 mg alfuzosin hydrochloride as the active ingredient. Alfuzosin hydrochloride is a white to off-white powder that melts at 231 to 233C. It is freely soluble in water, sparingly solub... |
Active Ingredient | Alfuzosin hydrochloride |
Dosage Form | Tablet, extended release |
Route | Oral |
Strength | 10mg |
Market Status | Prescription |
Company | Wockhardt; Teva Pharms; Apotex; Aurobindo Pharma; Torrent Pharms; Invagen Pharms; Sun Pharma Global; Mylan |
4 of 4 | |
---|---|
Drug Name | Uroxatral |
PubMed Health | Alfuzosin (By mouth) |
Drug Classes | Benign Prostatic Hypertrophy Agent |
Drug Label | Each UROXATRAL extended-release tablet contains 10 mg alfuzosin hydrochloride as the active ingredient. Alfuzosin hydrochloride is a white to off-white crystalline powder that melts at approximately 240C. It is freely soluble in water, sparingly so... |
Active Ingredient | Alfuzosin hydrochloride |
Dosage Form | Tablet, extended release |
Route | Oral |
Strength | 10mg |
Market Status | Prescription |
Company | Covis Pharma Sarl |
Urological Agents
Drugs used in the treatment of urological conditions and diseases such as URINARY INCONTINENCE and URINARY TRACT INFECTIONS. (See all compounds classified as Urological Agents.)
Adrenergic alpha-1 Receptor Antagonists
Drugs that bind to and block the activation of ADRENERGIC ALPHA-1 RECEPTORS. (See all compounds classified as Adrenergic alpha-1 Receptor Antagonists.)
Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.
Certificate Number : R1-CEP 2003-098 - Rev 02
Issue Date : 2021-08-18
Type : Chemical
Substance Number : 1287
Status : Valid
NDC Package Code : 63278-0500
Start Marketing Date : 2004-01-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Ankuk Pharmaceutical Co., Ltd.
Registration Date : 2020-07-02
Registration Number : 20200115-209-J-260(1)
Manufacturer Name : Farmak, as
Manufacturer Address : Na vlcinci 16/3, Klasterni Hradisko, 779 00 Olomouc, Czech Republic
Available Reg Filing : ASMF |
Octavius has been empowering lives since 1980 by providing quality products like DC granules, APIs and FDFs.
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 11976
Submission : 1996-05-14
Status : Inactive
Type : II
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 20888
Submission : 2007-09-27
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 20439
Submission : 2007-04-06
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19675
Submission : 2006-08-10
Status : Active
Type : II
NDC Package Code : 66039-826
Start Marketing Date : 2006-08-10
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 22638
Submission : 2009-03-30
Status : Active
Type : II
Certificate Number : CEP 2008-294 - Rev 01
Issue Date : 2024-11-07
Type : Chemical
Substance Number : 1287
Status : Valid
Date of Issue : 2022-06-17
Valid Till : 2025-07-21
Written Confirmation Number : WC-0062
Address of the Firm :
NDC Package Code : 53747-019
Start Marketing Date : 2009-03-31
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Ace Biopharm Co., Ltd.
Registration Date : 2019-10-10
Registration Number : 20191010-209-J-253
Manufacturer Name : Unichem Laboratories Limited
Manufacturer Address : Plot No. 197, Sector-1, Pithampur, Dist. Dhar (M.P.), India
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 20888
Submission : 2007-09-27
Status : Active
Type : II
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 11976
Submission : 1996-05-14
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 20307
Submission : 2007-02-24
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19180
Submission : 2006-08-07
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19675
Submission : 2006-08-10
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 20350
Submission : 2007-03-13
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19786
Submission : 2006-12-01
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 20379
Submission : 2007-03-28
Status : Inactive
Type : II
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
A Alfuzosin Hydrochloride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Alfuzosin Hydrochloride, including repackagers and relabelers. The FDA regulates Alfuzosin Hydrochloride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Alfuzosin Hydrochloride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Alfuzosin Hydrochloride manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Alfuzosin Hydrochloride supplier is an individual or a company that provides Alfuzosin Hydrochloride active pharmaceutical ingredient (API) or Alfuzosin Hydrochloride finished formulations upon request. The Alfuzosin Hydrochloride suppliers may include Alfuzosin Hydrochloride API manufacturers, exporters, distributors and traders.
click here to find a list of Alfuzosin Hydrochloride suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Alfuzosin Hydrochloride DMF (Drug Master File) is a document detailing the whole manufacturing process of Alfuzosin Hydrochloride active pharmaceutical ingredient (API) in detail. Different forms of Alfuzosin Hydrochloride DMFs exist exist since differing nations have different regulations, such as Alfuzosin Hydrochloride USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Alfuzosin Hydrochloride DMF submitted to regulatory agencies in the US is known as a USDMF. Alfuzosin Hydrochloride USDMF includes data on Alfuzosin Hydrochloride's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Alfuzosin Hydrochloride USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Alfuzosin Hydrochloride suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Alfuzosin Hydrochloride Drug Master File in Korea (Alfuzosin Hydrochloride KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Alfuzosin Hydrochloride. The MFDS reviews the Alfuzosin Hydrochloride KDMF as part of the drug registration process and uses the information provided in the Alfuzosin Hydrochloride KDMF to evaluate the safety and efficacy of the drug.
After submitting a Alfuzosin Hydrochloride KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Alfuzosin Hydrochloride API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Alfuzosin Hydrochloride suppliers with KDMF on PharmaCompass.
A Alfuzosin Hydrochloride CEP of the European Pharmacopoeia monograph is often referred to as a Alfuzosin Hydrochloride Certificate of Suitability (COS). The purpose of a Alfuzosin Hydrochloride CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Alfuzosin Hydrochloride EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Alfuzosin Hydrochloride to their clients by showing that a Alfuzosin Hydrochloride CEP has been issued for it. The manufacturer submits a Alfuzosin Hydrochloride CEP (COS) as part of the market authorization procedure, and it takes on the role of a Alfuzosin Hydrochloride CEP holder for the record. Additionally, the data presented in the Alfuzosin Hydrochloride CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Alfuzosin Hydrochloride DMF.
A Alfuzosin Hydrochloride CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Alfuzosin Hydrochloride CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Alfuzosin Hydrochloride suppliers with CEP (COS) on PharmaCompass.
A Alfuzosin Hydrochloride written confirmation (Alfuzosin Hydrochloride WC) is an official document issued by a regulatory agency to a Alfuzosin Hydrochloride manufacturer, verifying that the manufacturing facility of a Alfuzosin Hydrochloride active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Alfuzosin Hydrochloride APIs or Alfuzosin Hydrochloride finished pharmaceutical products to another nation, regulatory agencies frequently require a Alfuzosin Hydrochloride WC (written confirmation) as part of the regulatory process.
click here to find a list of Alfuzosin Hydrochloride suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Alfuzosin Hydrochloride as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Alfuzosin Hydrochloride API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Alfuzosin Hydrochloride as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Alfuzosin Hydrochloride and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Alfuzosin Hydrochloride NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Alfuzosin Hydrochloride suppliers with NDC on PharmaCompass.
Alfuzosin Hydrochloride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Alfuzosin Hydrochloride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Alfuzosin Hydrochloride GMP manufacturer or Alfuzosin Hydrochloride GMP API supplier for your needs.
A Alfuzosin Hydrochloride CoA (Certificate of Analysis) is a formal document that attests to Alfuzosin Hydrochloride's compliance with Alfuzosin Hydrochloride specifications and serves as a tool for batch-level quality control.
Alfuzosin Hydrochloride CoA mostly includes findings from lab analyses of a specific batch. For each Alfuzosin Hydrochloride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Alfuzosin Hydrochloride may be tested according to a variety of international standards, such as European Pharmacopoeia (Alfuzosin Hydrochloride EP), Alfuzosin Hydrochloride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Alfuzosin Hydrochloride USP).
LOOKING FOR A SUPPLIER?